Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...

Given that Ventura Securities has set a two-year target price of Rs 176, the broking firm thinks that the shares of NHPC ...

Ameluz-photodynamic therapy in superficial basal cell carcinoma may improve the clearance of target lesions, as shown in ...

Cipla share price had fallen after the company's September quarter results as analysts cut their target price, citing weaker than expected domestic business and challenges in its key products.

The clearance of Cipla's Goa facility opens the doors for the launch of Abraxane, which could be a around $120 million opportunity at peak.